A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab

Background: Immune responses play an important role in the development of breast cancer. Trastuzumab can activate antibody-dependent cellular cytotoxicity (ADCC) in human epidermal growth factor receptor-2 (HER-2)-positive breast cancer. Many studies have demonstrated that inflammatory markers, such...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Manag Res
Main Authors: Hong, Jin, Chen, Xiaosong, Gao, Weiqi, Zhu, Siji, Wu, Jiayi, Huang, Ou, He, Jianrong, Zhu, Li, Chen, Weiguo, Li, Yafen, Fei, Xiaochun, Lin, Lin, Shen, Kunwei
Format: Artigo
Jezik:Inglês
Izdano: Dove 2019
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6497860/
https://ncbi.nlm.nih.gov/pubmed/31114373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S187233
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki